Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The conversation is about finding a legitimate online source for 17α-estradiol (Alfatradiol) powder to make a 0.1% solution for hair loss treatment. A user suggests Anagenica as a source.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

A user seeks a topical hair loss treatment without minoxidil, considering options like finasteride, dutasteride, caffeine, tretinoin, or prostaglandin analogues. Recommendations include products like Strut, Maximus, Zeuss, and custom formulas from compounding pharmacies.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

A user seeks a lotion for an inflamed, itchy scalp caused by DHT, asking for options that promote blood flow and contain hair vitamins like caffeine and biotin. Another user suggests using a mix of mustard oil and coconut oil.

Topical melatonin may help with inflammation-induced hair loss. The user plans to try it and share results.

Scalp sunburns can cause permanent hair loss, so wearing UPF hats is essential. Tretinoin and Tacrolimus users should be cautious of increased photosensitivity and potential scalp issues.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

A user with seborrheic dermatitis and traction alopecia is seeking alternatives to minoxidil for hair loss, considering rosemary oil for its anti-inflammatory properties. They express concerns about potential side effects and effectiveness of various treatments, including rosemary oil, caffeine, and Redensyl.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

Iontophoresis and sonophoresis can enhance drug delivery into the scalp. Combining these methods may improve the effectiveness of topical treatments like dutasteride and certain peptides.

RU58841 should be stored in the refrigerator to maintain efficacy, but it remains stable for over two years even without refrigeration. A user prefers using Minoxidil and finasteride instead.

The post is about Bryan Johnson's hair loss regimen, which includes dutasteride mesotherapy, minoxidil, microneedling, and red laser therapy. The conversation includes discussions about the effectiveness of topical dutasteride and speculation about whether Bryan Johnson has had a hair transplant.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

Hair loss discussion includes fluridil (eucapil) and alfatradiol. Users share improvement experiences and alternative treatments in comments.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

The user plans to use a "nuclear protocol" for hair improvement, including topical minoxidil 12.5%, topical finasteride 0.1%, and tretinoin 0.05%, with microneedling once a week. They have seen improvements with minoxidil and are seeking opinions on their approach to achieve thicker hair.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The conversation discusses hair regrowth using 0.1% finasteride, 5% minoxidil, 1% retinoid, weekly microneedling, and red light therapy, with noticeable improvement in a short time. One person is curious about the retinoid application process when used with minoxidil.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

The user experienced hair loss possibly due to scalp damage and tried natural treatments with limited success. They reported noticeable hair thickening after using a laser treatment device, suggesting it may be effective, especially for those on finasteride.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The conversation discusses hair loss treatments, specifically the effectiveness and legitimacy of low-level laser therapy (LLLT) devices under $200. The user has seen positive results with finasteride, minoxidil, ketoconazole, microneedling, and scalp massages, and seeks advice on affordable LLLT options.